Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02097134 · OUTCOME

Vision Acuity, Assessed According to the Amblyopia Treatment Study Visual Acuity Testing Protocol

Intra-arterial Melphalan in Treating Younger Patients With Unilateral Retinoblastoma · Source last updated 2023-10-13

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
Not reported
Unit
Not reported
Interval / dispersion
Not reported
Time frame
1 year after therapy

What was measured

Estimated by the average visual acuity amongst patients evaluated with a 95% confidence interval.

Analysis population: The study was terminated at stage I since the therapy was considered not feasible to deliver. No patients had this data available. Patients either had affected eye enucleated, or did not complete protocol therapy.

Groups in this outcome

Melphalan

Patients will receive 1 intra-arterial injection (IA) of melphalan every 21- 30 days. Injections may be repeated every 21-30 days (up to a maximum of 3 cycles) assuming the patients meets the criteria to begin the next cycle.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Melphalan0

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields
denoms
  1. counts
    1. group Id
      OG000
      value
      0
    units
    Participants
description
Estimated by the average visual acuity amongst patients evaluated with a 95% confidence interval.
groups
  1. description
    Patients will receive 1 intra-arterial injection (IA) of melphalan every 21- 30 days. Injections may be repeated every 21-30 days (up to a maximum of 3 cycles) assuming the patients meets the criteria to begin the next cycle.
    id
    OG000
    title
    Melphalan
population Description
The study was terminated at stage I since the therapy was considered not feasible to deliver. No patients had this data available. Patients either had affected eye enucleated, or did not complete protocol therapy.
reporting Status
POSTED
time Frame
1 year after therapy
title
Vision Acuity, Assessed According to the Amblyopia Treatment Study Visual Acuity Testing Protocol
type
SECONDARY

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice